Open access
Oct 2026
Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.
Positive OS results with a clinically relevant benefit of ribociclib plus NSAI are demonstrated, consistent with the increasing reduction in recurrence risk, and reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.
D. Slamon, G. Hortobagyi, D. Stroyakovskiy et al.
· Annals of Oncology · 1 citation